MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Uždarymo kaina

2.74 6.61

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.4699999999999998

Max

2.77

Pagrindiniai rodikliai
By Trading Economics
Pajamos	64M 57M
Pardavimai	65M 67M
P/E Sektoriaus vid.	5.737 66.418
Pelno marža	84.425
Darbuotojai	75
EBITDA	63M 56M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+81.01% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-18

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-4.8M 207M
Ankstesnė atidarymo kaina	-3.87
Ankstesnė uždarymo kaina	2.74

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

1.25 / 1.48 Palaikymas ir pasipriešinimas

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-13 23:25; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026-04-13 22:45; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026-04-13 18:03; UTC

Uždarbis

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026-04-13 23:58; UTC

Uždarbis

Review & Preview: Earnings Time -- Barrons.com

2026-04-13 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026-04-13 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026-04-13 23:20; UTC

Rinkos pokalbiai

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026-04-13 23:01; UTC

Uždarbis

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026-04-13 23:01; UTC

Uždarbis

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026-04-13 23:01; UTC

Uždarbis

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026-04-13 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026-04-13 21:26; UTC

Svarbiausios naujienos

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026-04-13 21:23; UTC

Uždarbis

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026-04-13 21:16; UTC

Uždarbis

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026-04-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-13 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026-04-13 19:59; UTC

Rinkos pokalbiai

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026-04-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026-04-13 19:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Correction to Precious Metals Market Talk on April 9

2026-04-13 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026-04-13 18:43; UTC

Rinkos pokalbiai

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

81.01% į viršų

12 mėnesių prognozė

Vidutinis 4.67 USD 81.01%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.